Jenny N Guo, Mark A Assmus, Nicholas S Dean, Matthew S Lee, Clarissa Wong, Jordan Rich, Jessica Helon, Mitchell M Huang, Amy E Krambeck
INTRODUCTION: We aimed to compare holmium laser enucleation of the prostate (HoLEP) outcomes in patients with and without neurologic diseases (ND). METHODS: A prospectively maintained database of patients undergoing HoLEP from January 2021 to April 2022 was reviewed. The following NDs were included: diabetes-related neuropathy/neurogenic bladder, Parkinson's disease, dementia, cerebrovascular accident, multiple sclerosis, traumatic brain injury, transient ischemic attack, brain/spinal tumors, myasthenia gravis, spinal cord injury, and other...
April 2, 2024: Canadian Urological Association Journal